Exscientia up on expansion of its cancer treatment pipeline

Exscientia

14/03/2023 18:28

** U.S.-listed shares of British AI-driven pharma co
Exscientia PLC  EXAI.O  up 1.95% at $6.8
    ** Co reports expansion of its cancer treatment pipeline
with two new wholly owned development candidates, EXS74539 and 
EXS73565
    ** The two inhibitors are designed to overcome critical
design challenges and identify high quality drug candidates with
potential increased probability of success - Co
    ** Clinical development enabling studies are underway and
EXAI expects to provide an update on further plans leveraging
its personalized medicine platform in the H2 of 2023 
    ** EXAI also says it will also present data on the discovery
and development of EXS74539 at an upcoming scientific conference
in H1 of 2023 
    ** Both molecules were funded through a 2019 collaboration
with Celgene, which was acquired by Bristol Myers Squibb Co
 BMY.N  
    ** BMY's options to the candidates have now lapsed and EXAI
maintains all worldwide rights to both compounds 
    ** In 2022, EXAI's U.S.-listed stock fell ~73% 

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))